CaseBioscience joins an ARPA-H effort to develop room-temperature cell therapy preservation, Novartis licenses an mRNA-encoded T-cell engager from Abogen, and AstraZeneca, Daiichi Sankyo, and Summit plan to combine Datroway with ivonescimab.
|Articles|April 8, 2015
Catalent Pharma Solutions Joins PBOA
Author(s)BioPharm International Editors
Cornell Stamoran, Catalent Pharma Solutions vice-president, is elected to the board of trustees of the Pharma & Biopharma Outsourcing Association.
Advertisement
The Pharma & Biopharma Outsourcing Association (PBOA) announced on April 8 that Catalent Pharma Solutions has joined the PBOA as a sustaining member. Cornell Stamoran, vice-president, corporate strategy and government affairs at Catalent and board member at Catalent Applied Drug Delivery Institute, has been elected to the PBOA’s Board of Trustees.
“Catalent Pharma Solutions is one of the world’s largest development and supply partners in the global pharmaceutical industry and we’re delighted to bring them into the Pharma & Biopharma Outsourcing Association,” said Gil Roth, president of the PBOA. “Cornell Stamoran’s extensive experience and strategic focus will be of great value to our Board as we advance our membership’s legislative, regulatory and business interests.”
“The outsourcing of drug product manufacturing has expanded significantly since I came to the advanced delivery technologies side of the industry in 1992. Today, outsourcing serves a critical role in ensuring consistent supply of prescription, OTC and consumer health products to our customers, and ultimately to patients. As a result, it is more important than ever for us to advocate for our interests, both legislative and regulatory. I’m pleased to represent Catalent, and to work to advance the Association’s goals, ” said Stamoran in a PBOA press statement.
Stamoran leads Catalent’s strategic planning and market intelligence efforts, and supports its government affairs, investor relations, global M&A and technology innovation, and acquisition activities. He has spent more than 25 years engaged with the health care industry, including 23 years in advanced drug and biologic delivery and outsourcing.
The Pharma & Biopharma Outsourcing Association is a nonprofit trade association dedicated to advancing the regulatory, legislative and general business interests of contract manufacturing organizations and contract development and manufacturing organizations.
Source:
Advertisement
Related to this article
LumaLex Law's Dustin Robinson explains why retatrutide compounding remains illegal regardless of the Seventh Circuit's pending classification ruling.
Artiva Biotherapeutics will present data on AlloNK, an allogeneic, non-genetically modified NK cell therapy given with rituximab, in refractory rheumatoid arthritis, Sjögren disease and systemic sclerosis at ACR Convergence 2026, ahead of a planned phase 3 trial in rheumatoid arthritis.
Novartis has secured an exclusive worldwide license to ABO2203, Abogen's investigational mRNA-encoded CD19xCD3 T-cell engager designed to produce the bispecific inside the body to reset B cells in autoimmune disease. The agreement also includes options on other programs built on Abogen's RNA platform.
The 15-month project could let living cell therapies ship and store at room temperature, cutting cold-chain costs that limit patient access.
A planned phase 3 trial will test the TROP2 ADC and PD-1/VEGF bispecific together in 1st-line triple-negative breast cancer.
Former FDA oncology reviewer Paz Vellanki, MD, PhD, of Precision for Medicine, discusses how CDER's ARC program supports novel end points such as ctDNA for rare diseases and why sponsors should engage FDA early.
Following an FDA meeting, Wave Life Sciences plans a single 2-year registrational trial of WVE-006, its GalNAc-conjugated RNA editing oligonucleotide for alpha-1 antitrypsin deficiency, with a 1-year interim analysis that could support accelerated approval based on biomarkers.
Advertisement
Advertisement